Cancer Commentary - Caring About Cancer

July 15th, 2008

Amgen’s Bone Loss Drug and Prostate Cancer

The results of a three-year pivotal Phase 3 placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer, showed positive top-line results.
Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, the essential regulator of osteoclasts […]

By Gloria Gamat -- 0 comments